NCT06685081

Dexmedetomidine for Improved Pain Relief and Recovery in Spine Surgery

Optimal-dose of Dexmedetomidine as Adjuvant to Epidural Local Anesthetic/Steroid Injectate to Improve Pain and Quality of Waking in Patients With Chronic Low Back Pain: A Randomized Case-control Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Menoufia University · Academic / Other
• Sex: All
• Age: 35 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Chronic low back pain (CLBP) is a prevalent condition causing significant pain, disability, and reduced quality of life. While various treatments like exercise, NSAIDs, and spinal manipulation are recommended, their effectiveness is limited. Epidural steroid injections can provide short-term relief but may not be cost-effective and have associated risks. Dexmedetomidine (DXM) is a selective α2-adrenergic agonist with analgesic properties. It has been used as an adjuvant to anesthetics and analgesics to enhance pain relief and reduce opioid consumption. Using DXM in conjunction with local anesthetics for regional blocks has shown promising results in improving analgesia and functional outcomes.

Conditions

• Pain, Postoperative

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	Dexmedetomidine was injected in dose of 0.25 µg/kg
DRUG	Dexmedetomidine	Dexmedetomidine was injected in dose of 0.5 µg/kg
DRUG	Dexmedetomidine	Dexmedetomidine was injected in dose of 0.75 µg/kg
DRUG	Dexmedetomidine	Dexmedetomidine was injected in dose of 1 µg/kg
DRUG	lidocaine and triamcinolone	2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection

Timeline

• Start date: 2024-07-01
• Primary completion: 2024-10-15
• Completion: 2024-11-01
• First posted: 2024-11-12
• Last updated: 2024-11-12

Locations

1 site across 1 country: Egypt